Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

mTOR inhibition improves immune function in the elderly

Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB · 2014 · Science Translational Medicine · Atlas ID MAN2014

What this study shows

Older volunteers took the rapalog everolimus (RAD001) before a flu shot, and their antibody response to the vaccine rose by about 20% at doses that were fairly well tolerated. The share of T cells carrying the exhaustion marker PD-1 also fell. The PEARL authors summarise the doses as 0.5 mg daily or 5 mg weekly for 6 weeks. This is the human result behind the weekly low-dose idea. Boundary: a stronger vaccine response is a lab marker, not fewer infections, and the later RTB101 trial (MAN2021) shows how that gap can matter.

Cited on mTOR drugs in development: RTB101

Abstract

ShowHide

Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all species studied to date, and in mice delays the onset of age-related diseases and comorbidities. However, it is unknown if mTOR inhibition affects aging or its consequences in humans. To begin to assess the effects of mTOR inhibition on human aging-related conditions, we evaluated whether the mTOR inhibitor RAD001 ameliorated immunosenescence (the decline in immune function during aging) in elderly volunteers, as assessed by their response to influenza vaccination.

Read the full abstract on PubMed →

At a glance

Evidence type H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type2 - Human Clinical Trial
Model systemHumans, RCT, older adults
JournalScience Translational Medicine
Year2014
Peer reviewedYes
Record last updated2026-10-01
SourceDOI 10.1126/scitranslmed.3009892 · PMID 25540326

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

InterventionEverolimus (RAD001), low dose
TargetmTORC1
ModelHuman – elderly adults, RCT
EffectImproved influenza vaccine response (~20%) and reduced PD-1 expression on T cells

In the Atlas

Related topics

EverolimusImmune function

Links in the pathway map

Open questions that cite this study

Answers that reference this study

More studies on this topic

Cite this paper

ShowHide 
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., Glass, D. J., & Klickstein, L. B. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3009892

@article{MAN2014,
  author       = {Mannick, J. B. and Del Giudice, G. and Lattanzi, M. and Valiante, N. M. and Praestgaard, J. and Huang, B. and Lonetto, M. A. and Maecker, H. T. and Kovarik, J. and Carson, S. and Glass, D. J. and Klickstein, L. B.},
  title        = {{mTOR inhibition improves immune function in the elderly}},
  journal      = {Science Translational Medicine},
  year         = {2014},
  doi          = {10.1126/scitranslmed.3009892},
  note         = {PMID: 25540326},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper. 

Barton, O. (2026). Oliver's mTOR Atlas (record MAN2014) [Data set]. https://mtor-atlas.org/study/MAN2014/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MAN2014,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MAN2014},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MAN2014/},
  doi          = {10.5281/zenodo.22059963}
}
Was this page useful?